Catherine Dargan

Catherine Dargan leads Covington’s Corporate and Mergers & Acquisitions practices, and has advised numerous companies on their important strategic transactions for over 25 years. She focuses her practice on M&A, including public and private, and strategic partnering arrangements from sales of emerging venture-backed companies to multi-billion dollar acquisitions, and corporate governance.

Catherine structures and negotiates both domestic and cross-border transactions, and regularly represents clients in numerous industries, including life sciences, technology, defense, consumer products, and gaming, education, and manufacturing. Recent highlights include representing Bristol-Myers Squibb in its acquisitions of Karuna Therapeutics for $14 billion and RayzeBio for $4.1 billion; Merck in its $1.3 billion acquisition of Elanco’s aquaculture business; Biogen in its up to $1.8 billion acquisition of Human Immunology Biosciences, Organon in its up to $1.2 billion acquisition of Dermavant Sciences and AbbVie in its $1.4 billion acquisition of Aliada Therapeutics, Inc.

Harvard Law School, JD, 1994; Stanford University, AB, 1991.